SOURCE: Industrial Info Resources

September 17, 2008 06:30 ET

MannKind Keeps the Faith in Inhaled Insulin With Opening of $114 Million Production Plant in Connecticut, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - September 17, 2008) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The MannKind Corporation (NASDAQ:MNKD) (Valencia, California) will unveil its new $114 million insulin system production plant in Danbury, Connecticut, today. Construction began last year on the project, which will produce, package and distribute the company's Technosphere insulin and inhaler. Earlier this year, Eli Lilly & Company (NYSE:LLY) (Indianapolis, Indiana), Novo Nordisk (NYSE:NVO) (Bagsvaerd, Denmark) and Pfizer Incorporated (NYSE:PFE) (New York, New York) all abandoned similar products that were designed to replace injections for people suffering from diabetes. MannKind, founded in 1991 by billionaire Alfred Mann, has firmly stayed the course with its development of the controversial product.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at, or browse other breaking industrial news stories at

Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to or visit us at

Related News Articles

War on Bio-Terror Has to Wait Until Pennsylvania Solves New $5.6 Million Laboratory's Ventilation Problems

From Boston to Beijing: Massachusetts Expands Biotech Trade Efforts in China

Pharmaceutical-Biotech Construction Update: $6.9 Billion of Capital/Maintenance Projects to Kick-Off in Third Quarter

Contact Information

  • Contact:
    Joe Govreau